key: cord-0912034-9ie7l2nb
authors: Becker, Andrew E.; Chiotos, Kathleen; McGuire, Jennifer L.; Bruins, Benjamin B.; Alcamo, Alicia M.
title: Intracranial Hypertension in Multisystem Inflammatory Syndrome in Children (MIS-C)
date: 2021-02-26
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.02.062
sha: 80c1076ab6ddbba5d3b68e11ca1fa4ccd4cc3278
doc_id: 912034
cord_uid: 9ie7l2nb

nan

Multisystem inflammatory syndrome in children (MIS-C) is characterized by fever and multiorgan system dysfunction. Neurologic complications of MIS-C are not well described. We present 4 patients with MIS-C who had intracranial hypertension and discuss the unique management considerations when this occurs concurrently with significant myocardial dysfunction.

Multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel pediatric disease that is being increasingly recognized by the medical community (1) . Although coronavirus disease 2019 (COVID-19) more commonly occurs in adults, MIS-C appears to be a clinical entity that predominates in children (2) . The pathogenesis is not yet well understood, but current evidence suggests MIS-C is caused by a rare but severe deleterious post-infectious inflammatory immune response following exposure to SARS-CoV-2. Common presenting symptoms include fever and gastrointestinal symptoms, followed in many cases by multi-organ system dysfunction and shock. Early in the pandemic, parallels were drawn between MIS-C and Kawasaki disease and Kawasaki disease shock syndrome (KDSS) due to overlap in symptomatology; however, over time, it has become clear that MIS-C is a distinct clinical entity.

Although the burden of gastrointestinal and cardiac manifestations in MIS-C has been described, few studies have characterized the spectrum and severity of acute neurologic dysfunction in this syndrome (2) . Initial reports described neurologic dysfunction in up to twothirds of children with MIS-C(3-8), including altered mental status, headache and less commonly status epilepticus(9), stroke(10), and cerebral edema (11) . Intracranial hypertension J o u r n a l P r e -p r o o f syndrome.

Herein, we present 4 patients hospitalized at our institution between April 2020 and October 2020 with MIS-C complicated by IH and myocardial dysfunction (Table I) to inform clinicians of the occurrence of IH in patients with MIS-C and highlight unique hemodynamic management considerations in children with concurrent IH and myocardial dysfunction.

A 14-year-old female with a history of oppositional defiant disorder presented in April 2020 with dyspnea in the setting of four days of fever, headache, emesis and diarrhea.

Examination was significant for tachycardia and hypotension. She was ill-appearing and in moderate distress, with a diffuse erythematous rash and increased work of breathing. Initial laboratory results were notable for lactic acidosis, leukocytosis with lymphopenia and a bandemia, elevated inflammatory markers, hyponatremia, and acute kidney injury (Table 2) .

Chest radiograph revealed diffuse multifocal opacities. SARS-CoV-2 PCR was negative. SARS-CoV-2 serology was positive for IgG antibodies, though results did not return until after discharge.

She received cefepime and doxycycline for possible toxic shock syndrome or tick-borne illness. Clinical course was complicated by respiratory failure and left ventricular dysfunction for which she was intubated. She required epinephrine, norepinephrine, and hydrocortisone to obtain goal mean arterial pressure (MAP) >65 mmHg. Vasopressors were weaned off by hospital day (HD) 6 with normalization of myocardial dysfunction. On HD7, echocardiogram revealed right coronary artery dilation, prompting treatment for presumed KDSS with aspirin, intravenous J o u r n a l P r e -p r o o f immunoglobulin (IVIG) 2mg/kg and a transition from hydrocortisone to intravenous methylprednisolone (IVMP) 2mg/kg per day for three days followed by a taper.

On HD9, the patient noted blurry vision and was found to have a cranial nerve VI palsy and bilateral papilledema on ophthalmologic examination. Brain magnetic resonance imaging (MRI) with and without contrast demonstrated restricted diffusion of optic nerve sheaths, flattening of the posterior sclera, and eversion of the optic discs, consistent with papilledema.

MRV demonstrated flattening of the left transverse and sigmoid sinuses, which may also be seen with elevated intracranial pressure. A subsequent lumbar puncture (LP) revealed elevated opening pressure (>36 cmH 2 0; high normal pediatric range 28 (12)) without pleocytosis (white blood cell (WBC) count 4). She was initiated on acetazolamide with subsequent improvement of her cranial nerve palsy.

The patient was discharged on HD15 to a rehabilitation facility on acetazolamide, aspirin, and a steroid taper. At two-month follow up, papilledema and coronary artery dilation had resolved, acetazolamide and aspirin were discontinued, and she was at her neurologic baseline, without clinically evident deficits.

A 6-year-old previously healthy female presented in May 2020 with four days of fever as well as rash, conjunctivitis, cracked lips, emesis and diarrhea (Table 1) . Examination was significant for altered mental status (irritability), tachycardia, hypotension, nuchal rigidity, scattered erythema, and a maculopapular rash. Initial laboratory results were notable for metabolic acidosis, anemia, lymphopenia, thrombocytopenia, elevated inflammatory markers, hyponatremia, hypokalemia, as well as elevated troponin and brain natriuretic peptide (BNP; Table 2 ). Initial SARS-CoV-2 PCR was negative but repeat test on HD2 was positive (cycle Clinical course was significant for left ventricular dysfunction, requiring epinephrine and milrinone to maintain a goal MAP >55 mmHg. These were weaned off by HD7 with normalization of her myocardial dysfunction.

The patient was treated with IVIG 2mg/kg and IVMP 2mg/kg per day for three days followed by a taper and initiated on aspirin. She continued to be febrile, prompting a second dose of IVIG 2 mg/kg on hospital day three, increase in IVMP to 30mg/kg/day, and eventually administration of anakinra, an IL-1 receptor antagonist. She was discharged home on HD12 on aspirin and a steroid taper. At the time of discharge, she was at her neurologic baseline, without clinically evident deficits.

A 13-year-old previously healthy female presented in August 2020 with five days of fever, headache, neck pain, myalgia, abdominal pain, and emesis (Table 1) . Examination was significant for fever, tachycardia, and hypotension and she was ill-appearing with waxing and waning mental status, neck tenderness and nuchal rigidity, and a diffusely tender abdomen.

Initial laboratory results were notable for lactic acidosis, leukocytosis with bandemia, anemia, thrombocytopenia, elevated inflammatory markers, and a coagulopathy ( Table 2) . Abdominal J o u r n a l P r e -p r o o f ultrasound revealed hepatosplenomegaly, enlarged mesenteric lymph nodes, and moderate free pelvic fluid. SARS-CoV-2 PCR was negative and SARS-CoV-2 serology was positive for IgG

antibodies. An LP obtained on HD1 showed elevated opening pressure (>38 cmH 2 0), pleocytosis (WBC count 218/µL with 90% segmented neutrophils), and elevated protein (140 mg/dL). She was initiated on broad-spectrum antibiotics, which were later narrowed to ceftazidime and doxycycline for possible meningitis. She was intubated in the setting of progressive shock and worsening encephalopathy. Hypertonic saline was administered as necessary to maintain serum sodium above 140 mmol/L. Subsequent HCTs on HD2, HD3, and HD5 and brain MRI with and without contrast on HD6 were normal. EEG demonstrated sedated sleep, without epileptiform abnormalities or seizures.

Clinical course was complicated by rapidly progressive biventricular dysfunction with worsening lactatemia requiring initiation of epinephrine, norepinephrine, vasopressin, milrinone, and stress-dosed hydrocortisone to maintain an initial goal MAP >85 mmHg. This MAP goal was set to optimize cerebral perfusion pressure given her known IH and significant altered mental status, with neurologic examination being the primary clinical endpoint informing titration of therapies, an approach informed by our prior institutional experience of observing IH in our MIS-C population. Her mental status slowly returned to baseline, and sodium and MAP goals were liberalized by HD3. Vasopressors were weaned off by HD8, and echocardiogram showed normalization of her myocardial dysfunction.

The patient was treated with IVIG 2mg/kg and IVMP 30mg twice daily. In the setting of continued fever, systemic inflammation, and myocardial dysfunction, IVMP was increased to 1g daily for three days on HD4 followed by a taper. A serum cytokine panel showed an IL-6 level of >1300 pg/mL (high normal: 3.5), prompting administration of tocilizumab, an IL-6 inhibitor.

She was initiated on enoxaparin and transitioned to aspirin. She was transferred to a rehabilitation facility on HD17 on a steroid taper and aspirin, and she was discharged home on HD27 at her neurologic baseline without clinically evident deficits.

A 12-year-old previously healthy male presented in October 2020 with two days of fever and emesis in the setting of five days of diarrhea (Table 1) . Examination was significant for fever, tachycardia, and hypotension with waxing and waning mental status, conjunctivitis, cracked lips, nuchal rigidity, and an S4 gallop with tender hepatomegaly. Initial laboratory results were notable for lactatemia, neutrophilic lymphopenic leukocytosis, elevated inflammatory markers, coagulopathy, hyponatremia, acute kidney injury, as well as elevated troponin and BNP (Table 2) . SARS-CoV-2 PCR was negative and SARS-CoV-2 serology was positive for IgG antibodies. HCT on HD1 was normal and an LP performed on HD2 showed an elevated opening pressure (34 cmH 2 0) without pleocytosis (WBC count 3). EEG demonstrated diffuse slowing with poor organization, reactivity, and variability, but without epileptiform discharges or seizure. Clinical course was significant for biventricular dysfunction, for which he was intubated to lessen metabolic demand and initiated on milrinone and epinephrine to maintain a goal MAP >60 mmHg.

The patient was treated with IVIG 2mg/kg and IVMP 30mg twice daily. IVMP was increased to 1g daily for three days on HD3 followed by a taper in the setting of continued myocardial dysfunction. He was initiated on enoxaparin and transitioned to aspirin. Vasopressors were weaned off on HD7 and subsequent echocardiogram showed normalization of myocardial dysfunction. He was discharged home on HD16 at his neurologic baseline, without clinically evident deficits.

We present four patients admitted to our pediatric intensive care unit with MIS-C who demonstrated clinical, LP, and/or neuroimaging evidence of IH. Notably, each patient had at least two symptoms of neurologic dysfunction at presentation, including blurry vision, headache, neck stiffness, and encephalopathy. Similar to existing MIS-C literature, each patient also had at least moderate myocardial dysfunction and required multiple vasopressors (2) (3) (4) 13, 14) . All patients received immunomodulatory treatment with at least high dose steroids and IVIG, and some received additional therapies. Although each had neuroimaging, none had dedicated cerebrovascular imaging to specifically look for the small vessel vasculitis seen in other MIS-Crelated organ dysfunction. However, neuroimaging obtained did not reveal an alternate primary cause of their IH, including sinus venous thrombosis. All patients returned to their neurologic baseline, though one required acetazolamide for symptoms of IH at discharge.

These four patients were a subset of 30 total patients seen at our institution from April-November 2020 with a diagnosis of MIS-C. During this time period, 23 patients (77%) had neurologic symptoms with MIS-C, though isolated headache was the neurological symptom in 17 of these patients. Other documented neurologic symptoms included encephalopathy or significant irritability, nuchal rigidity, numbness, and vision impairment. These were the only four patients with LPs obtained, as they were the only patients with papilledema (patient 1) or clinical concern for significant irritability or meningismus (patients 2-4; present on presentation).

The incidence of neurologic symptoms in MIS-C is not well-described in the literature, but it may be as high as 58% (3) (4) (5) (6) in small cohort studies and up to 71% in severe cases (8) .

Additionally, subtle neurologic symptoms may be missed in a critically ill child if they are unable to offer subjective complaints. Although the neurologic symptoms seen in MIS-C are J o u r n a l P r e -p r o o f similar to those seen in Kawasaki disease, the incidence appears to be higher in MIS-C, though further studies are needed to evaluate this observation (15) . The etiology of these neurologic symptoms remains unclear but is likely multifactorial. Among those lumbar punctures reported in patients with MIS-C, at least one-quarter were abnormal (3, 4, 16) . However, these data are limited, as lumbar punctures may not be performed in affected patients with hemodynamic instability and, when they are, opening pressures are not always routinely obtained. Additionally, immunomodulatory treatment administered prior to LP may induce an aseptic meningitis subsequently incorrectly attributed to MIS-C(17). We do not feel that the medical management for MIS-C confounded our findings of IH in these patients because all but one demonstrated symptoms prior to the initiation of immunomodulatory therapies and half of the lumbar punctures were obtained prior to the start of these therapies. Regarding neuroimaging evaluation, one previous report described non-specific T2 abnormalities in the splenium of the corpus callosum in four children with neurologic dysfunction in a larger cohort of 27 children with MIS-C(16). This case series suggests that IH may be one etiology of neurologic dysfunction that could go unrecognized; a high index of suspicion must therefore be maintained, even when presenting neurologic symptoms are non-specific.

There is a high prevalence of myocardial dysfunction in patients admitted to the intensive care unit with MIS-C (3, 4, 13, 14) , with roughly one-half to three-quarters of patients requiring some form of inotropic support (2, 14) . Optimal management of this dysfunction requires that cardiac strain be minimized via afterload reduction while still meeting the minimum required driving pressure for adequate end-organ perfusion. Cerebral perfusion pressure is a function of mean arterial pressure and intracranial pressure (CPP = MAP -ICP), such that if ICP is higher than expected, there is a risk of underestimation of the MAP necessary to generate J o u r n a l P r e -p r o o f adequate CPP to prevent ischemic injury. Given our experience with this series of patients, we advocate for discussion of optimal MAP goals for MIS-C patients with evidence of neurologic dysfunction and possible IH. Although optimal MAP targets are unknown, close monitoring of mental status, cerebral perfusion, and other clinical and laboratory markers of end-organ perfusion could aid assessment of perfusion pressure adequacy. Additionally, further consideration of higher serum sodium targets, acetazolamide, or other strategies utilized in other causes of IH should play in the management of these patients is warranted.

We present this case series of patients with MIS-C-associated IH to facilitate awareness of a critical complication of this disease that may impact systemic management, and to raise questions requiring further investigation and discussion in the medical community. With a heightened clinical suspicion for IH and other neurologic manifestations of MIS-C, we hope to set the stage for a better understanding both of their incidence and of their impact on long term patient outcomes. 

CDC. Multisystem Inflammatory Syndrome in Children (MIS-C)

Multisystem inflammatory syndrome in children: A systematic review

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet

Kawasakilike multisystem inflammatory syndrome in children during the covid-19 pandemic

Multisystem Inflammatory Syndrome in Children in New York State

A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection

Neurological involvement associated with COVID-19 infection in children

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Multisystem Inflammatory Syndrome in Children Associated with Status Epilepticus

COVID-19 associated arterial ischaemic stroke and multisystem inflammatory syndrome in children: a case report

Fatal Cerebral Edema in a Child with COVID-19

Reference Range for Cerebrospinal Fluid Opening Pressure in Children

Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection

Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation

Neurological involvement in Kawasaki disease: a retrospective study. Pediatr Rheumatol

Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease

J o u r n a l P r e -p r o o f 1 lumbar puncture performed after administration of IVIG and steroids 2 cytokine profile performed after administration of steroids 3 IVMP dosed at 2mg/kg per day (max 30mg twice daily) 4 IVMP initially dosed at 2mg/kg per day (max 30mg twice daily) and subsequently increased to 30mg/kg per day (max 1g per day) Abbreviations: EEG = electroencephalogram, HCT = head computed tomography, ICP = intracranial pressure, IFN-g = interferon-gamma, IL = interleukin, IV = intravenous, IVIG = intravenous immunoglobulin, IVMP = intravenous methylprednisolone, LV = left ventricle, MRA = magnetic resonance angiography, MRI = magnetic resonance imaging, MRV = magnetic resonance venography, OP = opening pressure, RBC = red blood cell count, RV = right ventricle, TNF-a = tumor necrosis factor alpha, WBC = white blood cell count +++ = significantly elevated, + = elevated